XLO vs. COYA, TCRX, CRDL, JMAC, EPRX, SAVA, DERM, VIGL, PROC, and CLYM
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Coya Therapeutics (COYA), TScan Therapeutics (TCRX), Cardiol Therapeutics (CRDL), Maxpro Capital Acquisition (JMAC), Eupraxia Pharmaceuticals (EPRX), Cassava Sciences (SAVA), Journey Medical (DERM), Vigil Neuroscience (VIGL), Procaps Group (PROC), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry.
Xilio Therapeutics vs.
Coya Therapeutics (NASDAQ:COYA) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.
Coya Therapeutics' return on equity of -31.63% beat Xilio Therapeutics' return on equity.
Coya Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500.
Coya Therapeutics has higher revenue and earnings than Xilio Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Coya Therapeutics received 7 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. Likewise, 95.00% of users gave Coya Therapeutics an outperform vote while only 75.00% of users gave Xilio Therapeutics an outperform vote.
Coya Therapeutics currently has a consensus price target of $16.25, suggesting a potential upside of 153.51%. Xilio Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 330.11%. Given Xilio Therapeutics' higher probable upside, analysts plainly believe Xilio Therapeutics is more favorable than Coya Therapeutics.
39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Coya Therapeutics' average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score.
Summary
Coya Therapeutics beats Xilio Therapeutics on 10 of the 13 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:XLO) was last updated on 2/22/2025 by MarketBeat.com Staff
